The End-Stage Renal Disease (ESRD) Pipeline report embraces in-depth commercial and clinical assessment of the End-Stage Renal Disease (ESRD) pipeline products from the pre-clinical developmental phase to the marketed phase.
The report covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, End-Stage Renal Disease (ESRD) collaborations, mergers, acquisition, funding, designations, and other product-related details.
End-Stage Renal Disease (ESRD) Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights about companies that are developing therapies for the treatment of End-Stage Renal Disease (ESRD) with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the End-Stage Renal Disease (ESRD) Treatment.
-
End-Stage Renal Disease (ESRD) key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
End-Stage Renal Disease (ESRD) Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the End-Stage Renal Disease (ESRD) market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
End-Stage Renal Disease (ESRD) Therapeutics Landscape
Diabetic nephropathy (DN) is one of the most common complications of diabetes and the leading cause of end-stage renal disease (ESRD). Approximately 30–40% of diabetes mellitus patients in the world progress to ESRD, which emphasizes the effect of genetic factors on DN.
End-Stage Renal Disease (ESRD) therapeutics market size is expected to increase during the forecast period owing to the growing prevalence of the disease and the expected launch of the emerging therapies.
End-Stage Renal Disease (ESRD) companies:
-
Aronora
-
Merck
-
Rockwell Medical Technologies
-
Dynavax Technologies Corporation
And many others.
End-Stage Renal Disease (ESRD) therapies covered in the report include:
-
Intravenous Triferic
-
AB002
-
MK-2060
And many more.
Request for Sample Pages @ End-Stage Renal Disease (ESRD) Emerging Therapies and Key Companies
Table of Content
1. Report Introduction
2. End-Stage Renal Disease (ESRD)
3. End-Stage Renal Disease (ESRD) Current Treatment Patterns
4. End-Stage Renal Disease (ESRD) – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. End-Stage Renal Disease (ESRD) Late Stage Products (Phase-III)
7. End-Stage Renal Disease (ESRD) Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. End-Stage Renal Disease (ESRD) Discontinued Products
13. End-Stage Renal Disease (ESRD) Product Profiles
14. End-Stage Renal Disease (ESRD) Key Companies
15. End-Stage Renal Disease (ESRD) Key Products
16. Dormant and Discontinued Products
17. End-Stage Renal Disease (ESRD) Unmet Needs
18. End-Stage Renal Disease (ESRD) Future Perspectives
19. End-Stage Renal Disease (ESRD) Analyst Review
20. Appendix
21. Report Methodology
*The table of contents is not exhaustive; the final content may vary.
Visit to get the sample report: https://www.delveinsight.com/sample-request/end-stage-renal-disease-pipeline-insight
Latest Healthcare Report by DelveInsight
Global Kinase Inhibitor in Autoimmune Diseases Market
DelveInsight’s “Global Kinase Inhibitor in Autoimmune Diseases Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Global Kinase Inhibitor in Autoimmune Diseases market size, shares, and trends analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/